Back to top
more

Exact Sciences (EXAS)

(Delayed Data from NSDQ)

$56.72 USD

56.72
1,625,021

+0.53 (0.94%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $56.60 -0.12 (-0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Exact Sciences (EXAS) Stock Moves -1.09%: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed the most recent trading day at $67.82, moving -1.09% from the previous trading session.

Zacks Equity Research

Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average

by Zacks Equity Research

Should investors be excited or worried when a stock crosses above the 20-day simple moving average?

Urmimala Biswas headshot

3 MedTech Stocks Likely to Beat Estimates This Earnings Season

by Urmimala Biswas

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.

Zacks Equity Research

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

Zacks Equity Research

Exact Sciences (EXAS) Stock Moves -0.46%: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed the most recent trading day at $67.14, moving -0.46% from the previous trading session.

Zacks Equity Research

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed the most recent trading day at $66.21, moving -1.88% from the previous trading session.

Zacks Equity Research

Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Exact Sciences (EXAS) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.

Zacks Equity Research

Here's How Much a $1000 Investment in Exact Sciences Made 10 Years Ago Would Be Worth Today

by Zacks Equity Research

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Zacks Equity Research

Exact Sciences (EXAS) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed at $67.82 in the latest trading session, marking a -0.6% move from the prior day.

Zacks Equity Research

Exact Sciences (EXAS) Stock Moves -0.67%: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed at $67.92 in the latest trading session, marking a -0.67% move from the prior day.

Zacks Equity Research

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Zacks Equity Research

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Zacks Equity Research

Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Zacks Equity Research

The Zacks Analyst Blog Highlights Jinko Solar, American Airlines and Exact Sciences

by Zacks Equity Research

Jinko Solar, American Airlines and Exact Sciences are included in this Analyst Blog.

Zacks Equity Research

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

Exact Sciences (EXAS) closed at $68.54 in the latest trading session, marking a +1.99% move from the prior day.

Derek Lewis headshot

3 Top Stocks Already up More Than 20% In 2023

by Derek Lewis

While inflation remains the market's primary concern, these three stocks have gotten off to a great start in 2023, already up more than 20% year-to-date. Can the strength continue? Their earnings outlooks suggest so.

Zacks Equity Research

Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCB

Zacks Equity Research

Zacks Market Edge Highlights: EXAS, ZM, TSLA, ABBV, ZOM

by Zacks Equity Research

EXAS, ZM, TSLA, ABBV, ZOM have been highlighted in this Market Edge article.

Tracey Ryniec headshot

The Stocks Behind 2022's Popular ETFs

by Tracey Ryniec

What stocks do popular ETF managers like Cathie Wood own in their portfolios?

Zacks Equity Research

Here's Why Investors Should Buy Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Zacks Equity Research

Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?

by Zacks Equity Research

Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.

Zacks Equity Research

3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.